Image

Pregnancy Outcomes Following Myomectomy

Pregnancy Outcomes Following Myomectomy

Recruiting
25-45 years
Female
Phase N/A

Powered by AI

Overview

The most prevalent genital pathology, uterine fibroids have a detrimental impact on the health of women. Fibroid symptoms are typically more impactful on females and frequently require uterine excision. Although contentious in terms of how it affects pregnancy outcomes, hysteroscopic, laparoscopic, or laparotomic myomectomy has always been a necessary and suitable procedure for the patient's health. Numerous studies have been conducted on the topic, but no clear findings have been reached.

The goal of this observational study is to investigate the pregnancy outcomes after hysteroscopic, laparoscopic, laparotomic myomectomies in female patients affected by fibroids. The main questions it aims to answer are:

To investigate pregnancy outcomes in relation to surgical approach used for myomectomy.

To investigate whether pregnancy outcome is different in relation to time when myomectomy was performed: on a pregnant uterus or on a non-gravid uterus.

If there is a comparison group: Researchers will compare a group of patients unsubmitted to surgery, to see the difference with the operated patients.

Participants will follow up, to evaluate the possible pregnancy complications, the intraoperative complications and other perinatal and post-operative complications.

Description

AIMS
  1. To investigate pregnancy outcomes in relation to surgical approach used for myomectomy.
  2. To investigate if pregnancy outcome is different in relation to time when myomectomy was performed: on a gravid uterus or on a non-gravid uterus

Patients enrolled are divided in three major groups:

  • Group A: myomectomy outside of pregnancy-A1 hysteroscopic; A2 laparoscopic; A3 laparotomy
  • Group B: myomectomy during CS: B1 trans-endometrial; B2 serosal
  • Group C: control group with repeated CS

INCLUSION CRITERIA:

  1. women of reproductive age (up to 45 yrs)-all groups
  2. women who had myomectomy (group A and B)/CS (group C) at least two years before the enrolment
  3. myomas 30 mm in size and larger (groups A and B)
  4. Study groups: myomectomy performed as hysteroscopic/laparoscopic/laparotomic myomectomy or cesarean myomectomy, both using transendometrial or serosal approach: gravida 2 para 2 or gravida 1 para 1 [groups A1, A2, A3 and groups B1 and B2]
  5. Control group: women who had cesarean section in their second pregnancy-para 2 gravida 2, at least two years after the CS [group C]

EXCLUSION CRITERIA:

  1. any previous surgery on reproductive organs except myomectomy
  2. any additional operation during cesarean myomectomy procedure except cesarean section
  3. history of endometriosis or PID
  4. coagulation disorders
  5. previous treatment for any malignant disease
  6. previous GTD
  7. premature ovarian failure or any kind of ovarian insufficiency necessitating oocyte donation
  8. systemic diseases: IBD, MS, DM

DATA TO COLLECT:

  1. age
  2. years after myomectomy or CS(for group C)
  3. gravidity
  4. parity
  5. BMI
  6. myoma characteristics (size and type)
  7. myomectomy procedure
  8. gestational week at delivery
  9. primary indication for CS
  10. fetal position
  11. placental pathology
  12. preoperative hematologic values
  13. postoperative hematologic values
  14. duration of the CS
  15. myoma recurrence in groups A and B
  16. uterine rupture
  17. perioperative transfusion
  18. febrile morbidity
  19. postoperative hospitalization in days
  20. PPH
  21. cause of PPH
  22. uterine atony
  23. relaparotomy
  24. hysterectomy
  25. blood vessels ligation
  26. fetal presentation: cephalic/other
  27. neonatal body weight
  28. Apgar score
    OUTCOMES
  29. pregnancy complications
  30. placental pathology: placenta previa, placental abruption, PAS
  31. PPROM (gestational age)
  32. abnormal presentation: cephalic/other
  33. uterine rupture: complete/incomplete
  34. preterm/term delivery (gestational age at delivery)
  35. intraoperative complications
  36. intraabdominal adhesions/PAI score
  37. surgery complications: Claven Dindo classification
  38. other complications:
  39. neonatal outcome,
  40. duration of maternal hospitalization,
  41. primary or secondary PPH
  42. primary or secondary PPH
  43. relaparotomy
  44. peripartum hysterectomy,
  45. ligation of major blood vessels (uterine, ovarian, iliac)

The study will be conducted as a multicentric observational study including cesarean section deliveries in each participating center. In each participating center, one person will be in charge for data collection and filling the SPSS database after obtaining the approval of the local Ethic Committee. As the study is observational and all the procedures will be conducted according to the local practice, informed consent from patients is not necessary.

Following data collection and termination of the study, a single researcher will oversee the SPSS data collection for all the participating centers, checking the quality of data and submitting it for statistical analysis.

Eligibility

Inclusion Criteria:

  1. women of reproductive age (up to 45 yrs)-all groups
  2. women who had myomectomy (group A and B)/CS (group C) at least two years before the enrolment
  3. myomas 30 mm in size and larger (groups A and B)
  4. Study groups: myomectomy performed as hysteroscopic/laparoscopic/laparotomic myomectomy or cesarean myomectomy, both using transendometrial or serosal approach: gravida 2 para 2 or gravida 1 para 1 [groups A1, A2, A3 and groups B1 and B2]
  5. Control group: women who had cesarean section in their second pregnancy-para 2 gravida 2, at least two years after the CS [group C]

Exclusion Criteria:

  1. any previous surgery on reproductive organs except myomectomy
  2. any additional operation during cesarean myomectomy procedure except cesarean section
  3. history of endometriosis or PID
  4. coagulation disorders
  5. previous treatment for any malignant disease
  6. previous GTD
  7. premature ovarian failure or any kind of ovarian insufficiency necessitating oocyte donation
  8. systemic diseases: IBD, MS, DM

Study details
    Uterine Fibroid
    Pregnancy Complications
    Reproductive Issues
    Reproductive Sterility

NCT06474065

Centro di Ricerca Clinica Salentino

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.